Insider Transactions Reported by 19 Insiders of Elevation Oncology, Inc.

Location: Boston, MA

Quick Takeaways

Elevation Oncology, Inc. has 19 insiders with reported activity on this page.
No net insider buy/sell flow is currently reported for the last year.
Recent transaction rows are available for direct filing-level review.

What Changed

No meaningful buy/sell imbalance is currently visible in the one-year window.
Activity will update as new Forms 3/4/5 are filed.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Source Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 18 Apr 2025.

Buys

Shares: 0

Insiders: 0

Sells

Shares: 0

Insiders: 0

Net

Shares: 0

Insiders: 0

Window (months)	Buy $	Sell $	Net $
0-3	$0	$0	$0
3-6	$0	$0	$0
6-9	$0	$0	$0
9-12	$0	$0	$0

Elevation Oncology, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Valuation	Report Date
Qiming U.S. Healthcare Fund II, L.P.	10%+ Owner	$1,208,772	Mixed	29 Jun 2021
Vertex Global HC Fund II Pte. Ltd.	10%+ Owner	$1,176,897	Mixed	29 Jun 2021
Cormorant Asset Management, LP	Former 10% Owner	$1,138,916	Mixed	29 Jun 2021
venBio Global Strategic Fund III, L.P.	10%+ Owner	$971,769	Mixed	25 May 2022
Joseph J. Ferra Jr.	CHIEF EXECUTIVE OFFICER, Director	$251,773	Mixed	16 Jun 2025
Valerie Malyvanh Jansen	Chief Medical Officer	$237,433	Mixed	15 Feb 2025
David Dornan	Chief Scientific Officer	$41,525	Mixed	15 Feb 2025
Tammy Furlong	Chief Financial Officer	$1,612	Mixed	23 Jul 2025
Timothy P. Clackson	Director	$0	Mixed	23 Jul 2025
Alan B. Sandler	Director		Mixed	23 Jul 2025
Shawn Leland	President, CEO, Director		Mixed	14 Feb 2022
Darcy Mootz	Director		Mixed	23 Jul 2025
Richard Gaster	Director		Mixed	24 Jun 2021
R. Michael Carruthers	Director		Mixed	23 Jul 2025
Lori Hu	Director		Mixed	16 Jun 2023
Steve Elms	Director		Mixed	23 Jul 2025
Colin Walsh	Director		Mixed	16 Jun 2023
Aisling Capital IV, LP	10%+ Owner		Mixed	16 Jun 2023
Julie M. Cherrington	Director		Mixed	23 Jul 2025

Top shareholders of Elevation Oncology, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
BIOTECHNOLOGY VALUE FUND L P	13D/G	BVF PARTNERS L P/IL	7%	4,440,000	$1,642,800	$0	31 Mar 2025	13D/G
Qiming U.S. Healthcare Fund II, L.P.	3/4/5	10%+ Owner	— class O/S missing	2,370,142	$1,208,772	—	29 Jun 2021	3/4/5
TANG CAPITAL MANAGEMENT LLC	13D/G	—	5%	3,115,000	$1,183,700	-$1,112,990	30 Jun 2025	13D/G
Vertex Global HC Fund II Pte. Ltd.	3/4/5	10%+ Owner	— class O/S missing	2,307,642	$1,176,897	—	29 Jun 2021	3/4/5
Cormorant Asset Management, LP	3/4/5	Former 10% Owner	— class O/S missing	2,233,168	$1,138,916	—	29 Jun 2021	3/4/5
venBio Global Strategic Fund III, L.P.	3/4/5	10%+ Owner	— class O/S missing	1,905,430	$971,769	—	25 May 2022	3/4/5
VANGUARD GROUP INC	13D/G	The Vanguard Group	4.4%	2,610,045	$965,717	$0	31 Dec 2024	13D/G
GOLDMAN SACHS GROUP INC	13D/G	THE GOLDMAN SACHS GROUP, INC.	2.8%	1,683,356	$622,842	$0	31 Dec 2024	13D/G
Joseph J. Ferra Jr.	3/4/5	CHIEF EXECUTIVE OFFICER, Director	— mixed-class rows	995,332 mixed-class rows	$251,773	—	16 Jun 2025	3/4/5
Valerie Malyvanh Jansen	3/4/5	CHIEF MEDICAL OFFICER	— mixed-class rows	409,811 mixed-class rows	$237,433	—	15 Feb 2025	3/4/5
BlackRock, Inc.	13D/G	—	0.6%	369,048	$135,478	-$1,025,726	30 Jun 2025	13D/G
David Dornan	3/4/5	CHIEF SCIENTIFIC OFFICER	— mixed-class rows	295,848 mixed-class rows	$41,525	—	15 Feb 2025	3/4/5
Tammy Furlong	3/4/5	CHIEF FINANCIAL OFFICER	— class O/S missing	2,100	$1,612	—	23 Jul 2025	3/4/5
Shawn Leland	3/4/5	President, CEO, Director	— class O/S missing	186,500	—	—	14 Feb 2022	3/4/5
Aisling Capital IV, LP	3/4/5	10%+ Owner	— class O/S missing	31,238	—	—	16 Jun 2023	3/4/5
Colin Walsh	3/4/5	Director	— class O/S missing	31,238	—	—	16 Jun 2023	3/4/5
Lori Hu	3/4/5	Director	— class O/S missing	31,238	—	—	16 Jun 2023	3/4/5
Richard Gaster	3/4/5	Director	— class O/S missing	31,238	—	—	24 Jun 2021	3/4/5

Recent Insider Transactions by Companies or Individuals for Elevation Oncology, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Shares	Shares Owned	Date	Ownership
Alan B. Sandler	ELEV	Stock Option (Right to Buy)	Disposed to Issuer	-100%	-125,000	0	23 Jul 2025	Direct
Darcy Mootz	ELEV	Stock Option (Right to Buy)	Disposed to Issuer	-100%	-125,000	0	23 Jul 2025	Direct
Steve Elms	ELEV	Stock Option (Right to Buy)	Disposed to Issuer	-100%	-148,095	0	23 Jul 2025	See footnote
Timothy P. Clackson	ELEV	Common Stock	Disposition pursuant to a tender of shares in a change of control transaction	-100%	-47,330	0	23 Jul 2025	The Timothy P. Clackson Irrevocable GST Trust of 2020
Timothy P. Clackson	ELEV	Stock Option (Right to Buy)	Disposed to Issuer	-100%	-116,857	0	23 Jul 2025	Direct
Julie M. Cherrington	ELEV	Stock Option (Right to Buy)	Disposed to Issuer	-100%	-125,000	0	23 Jul 2025	Direct
R. Michael Carruthers	ELEV	Stock Option (Right to Buy)	Disposed to Issuer	-100%	-164,187	0	23 Jul 2025	Direct
Tammy Furlong	ELEV	Common Stock	Disposition pursuant to a tender of shares in a change of control transaction	-100%	-37,957	0	23 Jul 2025	Direct
Tammy Furlong	ELEV	Stock Option (Right to Buy)	Disposed to Issuer	-100%	-828,387	0	23 Jul 2025	Direct
Joseph J. Ferra Jr.	ELEV	Common Stock	Tax liability	-3.09%	-4,627	145,085	16 Jun 2025	Direct
Joseph J. Ferra Jr.	ELEV	Common Stock	Options Exercise	9.16%	12,560	149,712	16 Jun 2025	Direct
Joseph J. Ferra Jr.	ELEV	Restricted Stock Unit	Options Exercise	-100%	-12,560	0	16 Jun 2025	Direct
Alan B. Sandler	ELEV	Stock Option (Right to Buy)	Award		35,000	35,000	05 Jun 2025	Direct
Darcy Mootz	ELEV	Stock Option (Right to Buy)	Award		35,000	35,000	05 Jun 2025	Direct
Steve Elms	ELEV	Stock Option (Right to Buy)	Award		35,000	35,000	05 Jun 2025	See footnote
Timothy P. Clackson	ELEV	Stock Option (Right to Buy)	Award		35,000	35,000	05 Jun 2025	Direct
Julie M. Cherrington	ELEV	Stock Option (Right to Buy)	Award		35,000	35,000	05 Jun 2025	Direct
R. Michael Carruthers	ELEV	Stock Option (Right to Buy)	Award		35,000	35,000	05 Jun 2025	Direct
Tammy Furlong	ELEV	Common Stock	Tax liability	-7.22%	-784	10,075	15 May 2025	Direct
Tammy Furlong	ELEV	Common Stock	Options Exercise	32.2%	2,643	10,859	15 May 2025	Direct
Tammy Furlong	ELEV	Restricted Stock Unit	Options Exercise	-55.7%	-2,643	2,100	15 May 2025	Direct
Joseph J. Ferra Jr.	ELEV	Common Stock	Tax liability	-1.65%	-2,303	137,152	15 May 2025	Direct
Joseph J. Ferra Jr.	ELEV	Common Stock	Options Exercise	4.69%	6,250	139,455	15 May 2025	Direct
Joseph J. Ferra Jr.	ELEV	Restricted Stock Unit	Options Exercise	-8.33%	-6,250	68,750	15 May 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.